Novo Nordisk A/s

Michael Paolo Bastner Sandrini

Jesper F Lau

Sven Hastrup

Henning Thoegersen

Paw Bloch

Kristian Sass-Oerum

Sebastian Beck Joergensen

Lotte Bjerre Knudsen

Allan Christian Shaw

Charlotte Helgstrand

Kim Vilbour Andersen

Nikolaj Kulahin Roed

Adam Paul Chambers

Anna Secher

Jim McGuire

Jim Mcguire

The invention relates to a construct comprising a compound targeting areas in the brain involved in the regulation of body weight and an allosteric ligand to a receptor located in the blood-brain barrier (BBB). The invention also relates to compositions and uses of such construct, for example in the prevention or treatment of overweight and obesity. Preferred compounds for regulation of body weight include GLP-1 receptor agonists (GLP-1RA), and preferred receptors located in the BBB include the transferrin receptor (TfR). Exemplary fusions and conjugates of GLP-1 RA's and anti TfR-Fab's exhibit an increased binding to brain regions expressing the GLP-1 receptor as compared to fusions or conjugates with inactive control Fab's, in particular in brain areas protected by the BBB. In vivo mice studies confirm increased reduction in food intake as well as weight loss for the active construct compared to the inactive one.

Compounds for treatment of obesity

The invention relates to MIC-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a MIC-1 protein or an analog thereof at the C-terminus of the fusion protein and a functional variant of human serum albumin at the N-terminus of the fusion protein connected via a peptide linker. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.

MIC-1 fusion proteins and uses thereof

Growing community of inventors

Bagsvaerd, Denmark

Michael Paolo Bastner Sandrini